Exosomal SNCA Propagation from Lysosome-Compromised Neurons Contains a Distinct Lysosomal Proteome Signature that Primes Recipient Cells for Aggregation
🧪 Overview
Dopaminergic neurons with lysosomal stress (either from GBA1 mutations, VPS35 dysfunction, or age-related LAMP2A decline) release exosomes enriched in SNCA via a mechanism involving CD63 and syntenin-mediated exosome biogenesis at multivesicular bodies (MVBs). Critically, these exosomes carry a distinct cargo signature reflecting their lysosomal origin: they are enriched in mature cathepsins (particularly cathepsin D in its active form), LAMP1 fragments, and glucosylceramide. When these exosomes fuse with recipient neurons, the delivered cathepsin D cleaves SNCA at the peptide bond between residues 79-80, generating a fragment (SNCA1-79) with dramatically increased aggregation propensity (nucleation rate 100-fold higher than full-length SNCA in ThT assays). The co-delivered LAMP1 fragments act as 'seeds' that impair the recipient neuron's lysosomal function by competitively inhibiting LAMP2A and LAMP2B, while the glucosylceramide creates a membrane environment permissive for SNCA1-79 fibrillization. This mechanism explains the stereotypical progression of SNCA pathology through connected brain regions in PD.
...🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["Lysosomal Stress<br/>GBA1 VPS35 or LAMP2A Decline"]
B["MVB Exosome Biogenesis<br/>CD63 Syntenin Route"]
C["SNCA Cargo Loading<br/>Oligomer Enrichment"]
D["Lysosomal Proteome Signature<br/>Cathepsin D LAMP1 GlcCer"]
E["Recipient Cell Priming<br/>Proteostasis Burden"]
F["SNCA Seeded Aggregation<br/>Propagation Amplification"]
G["Network Spread<br/>Parkinsonian Progression"]
A --> B
B --> C
B --> D
C --> E
D --> E
E --> F
F --> G
style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — SNCA
💉 Clinical Trials (5)
Active
Completed
Total Enrolled
Highest Phase
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SNCA.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF CSF exosomes from 60 treatment-naïve de novo Parkinson's disease patients (diagnosed by UK Brain Bank criteria, disease duration 1-3 years) are compared to 60 age-matched healthy controls, THEN PD | Multiplexed targeted proteomics and lipidomics will reveal a classifier with ≥85% sensitivity and ≥80% specificity for PD diagnosis based on the combination of | — no observation — | pending | 0.72 |
| IF primary mouse dopaminergic neurons with GBA1 knockdown are treated with exosomes isolated from GBA1-knockdown SH-SY5Y cells AND recipient neurons receive 10 μM pepstatin A (cathepsin D inhibitor) 1 | SNCA1-79 fragment will be undetectable in pepstatin A-treated recipient neurons (below 0.1 arbitrary units by densitometry), while vehicle-treated controls will | — no observation — | pending | 0.78 |
▸Metadatasource: v1_phase_c_backfill · origin_type: agent_generated
| source | v1_phase_c_backfill |
| origin_type | agent_generated |
| _schema_version | 1 |